Dander et al. [65] identified and validated interleukin 2 receptor alpha (IL-2Rα), tumor necrosis factor receptor (TNFR) I, and elafin as reliable to predict the response of patients with GVHD to MSCs. This evidence concerns the gene IL2RA and graft versus host disease.